Apollomics, Inc. (NASDAQ:APLM) Sees Significant Drop in Short Interest

Apollomics, Inc. (NASDAQ:APLM) was the target of a large decrease in short interest in the month of October. As of October 31st, there was short interest totalling 168,500 shares, a decrease of 49.5% from the October 15th total of 333,700 shares. Based on an average trading volume of 3,690,000 shares, the short-interest ratio is presently 0.0 days. Approximately 0.3% of the shares of the company are sold short.

Apollomics Stock Performance

APLM opened at $0.11 on Thursday. The company’s 50-day simple moving average is $0.13 and its two-hundred day simple moving average is $0.19. Apollomics has a 52-week low of $0.11 and a 52-week high of $1.79.

Hedge Funds Weigh In On Apollomics

An institutional investor recently raised its position in Apollomics stock. George Kaiser Family Foundation raised its stake in shares of Apollomics, Inc. (NASDAQ:APLM) by 2,585.6% during the 2nd quarter, according to its most recent filing with the SEC. The firm owned 670,976 shares of the company’s stock after acquiring an additional 645,992 shares during the period. Apollomics makes up approximately 0.0% of George Kaiser Family Foundation’s holdings, making the stock its 18th biggest position. George Kaiser Family Foundation owned approximately 0.75% of Apollomics worth $141,000 as of its most recent SEC filing. Institutional investors own 19.13% of the company’s stock.

Apollomics Company Profile

Apollomics, Inc, a clinical-stage biopharmaceutical company, engages in the discovery and development of oncology therapies to harness the immune system and target specific molecular pathways to eradicate cancer. The company’s products portfolio includes Vebreltinib (APL-101), an oral active, highly selective c-Met inhibitor, which is in Phase 2 clinical trials for treatment of non-small cell lung cancer; APL-102, an oral active, small molecule Multiple Tyrosine Kinase Inhibitor, which is in a in a Phase 1 clinical trial to inhibit various kinases that are aberrantly activated in cancer cells; and APL-122, a tumor inhibitor candidate, targeting ErbB1/2/4 signaling pathwaysthat is in Phase 1 dose escalation clinical trials to treat cancers within the brain.